Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial-Reference-Cited by-同舟云学术

Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial

Published:2022-01 Issue:10321 Volume:399 Page:237-248
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Halperin Scott A,Ye Lingyun,MacKinnon-Cameron Donna,Smith Bruce,Cahn Pedro E,Ruiz-Palacios Guillermo M,Ikram Aamer,Lanas Fernando,Lourdes Guerrero M,Muñoz Navarro Sergio Raúl,Sued Omar,Lioznov Dmitry A,Dzutseva Vitalina,Parveen Ghazala,Zhu Fengcai,Leppan Laura,Langley Joanne M,Barreto Luis,Gou Jinbo,Zhu Tao,Mao Helen,Gagnon Luc,Tran Steven-Phay,Khan Sarwat Tahsin,Becerra Aquino Amalia Guadalupe,Saldaña Montemayor Edgar Eduardo,Rivera Martínez Norma Eréndira,Bohórquez López Víctor Casildo,Simón Campos J. Abraham,Pineda Cárdenas Felipe de Jesús,Chen Wei,Hou Lihua,Zhang Zhe,Corral Gonzalo,López Eduardo,Teijeiro Ricardo,Alzogaray Maria F.,Zaidman Cesar,Lopardo Gustavo,Goecke Bernardo,Feijooó Seoane Rosa María,Mahmood Sayed Faisal,Khan Ejaz Ahmed,Akram Jayed,Abbas Salma,Salahuddin Naseem,Rozhkova Elena,Zubkova Tatyana

Funder

Beijing Institute of Technology

Publisher

Elsevier BV

Subject

General Medicine

Reference14 articles.

1. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial;Zhu;Lancet,2020

2. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial;Zhu;Lancet,2020

3. The asymptotic properties of nonparametric tests for comparing survival distributions;Schoenfeld;Biometrika,1981

4. Group sequential methods with applications to clinical trials;Jennison,1999

5. Checking the Cox model with cumulative sums of martingale-based residuals;Lin;Biometrika,1993

Cited by 132 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lipid nanoparticle-encapsulated DNA vaccine robustly induce superior immune responses to the mRNA vaccine in Syrian hamsters;Molecular Therapy - Methods & Clinical Development;2024-03

2. Autoimmune response after SARS-CoV-2 infection and SARS-CoV-2 vaccines;Autoimmunity Reviews;2024-03

3. COVID-19 Vaccines: Where Did We Stand at the End of 2023?;Viruses;2024-01-29

4. Effect of Platform Type on Clinical Efficacy of SARS-CoV-2 Vaccines in Prime Vaccination Settings: A Systematic Review and Meta-Regression of Randomized Controlled Trials;Vaccines;2024-01-26

5. One HA stalk topping multiple heads as a novel influenza vaccine;Emerging Microbes & Infections;2024-01-22